<DOC>
	<DOCNO>NCT00193050</DOCNO>
	<brief_summary>Treatment strategy include induction chemotherapy several potential advantage : early initiation systemic chemotherapy , vivo assessment response , down-staging primary tumor regional lymphatic metastasis , make breast conservation option many . The aim present study determine efficacy toxicity induction combination chemotherapy triplet , gemcitabine , epirubicin , docetaxel , patient locally advance inflammatory breast cancer . Clearly , upfront treatment well adjuvant treatment breast cancer , effective new agent combination agent likely great potential impact .</brief_summary>
	<brief_title>Weekly Gemcitabine , Epirubicin , Docetaxel Locally Advanced Inflammatory Breast Cancer</brief_title>
	<detailed_description>Upon determination eligibility , patient receive : Gemcitabine + Epirubicin + Docetaxel</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Inflammatory Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>To include study , must meet following criterion : Adenocarcinoma breast confirm biopsy Female Patients &gt; 18 year age Normal cardiac function Ability perform activity daily live minimal assistance Chemotherapy na√Øve receive prior chemotherapy &gt; 5 year ago Adequate bone marrow , liver kidney function Be inform investigational nature study Sign inform consent form Sentinel lymph node and/or axillary dissection prior enrollment You participate study follow apply : Life expectancy &lt; 6 month History significant heart disease Prior chemotherapy hormonal therapy Concurrent Trastuzumab therapy History significant psychiatric disorder History active uncontrolled infection Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>